调节肠道菌群,能改善NAFLD吗?(综述)
创作:docxyxy 审核:mildbreeze 04月01日
  • 肠道菌群通过肠-肝轴可促进非酒精性脂肪性肝病(NAFLD)的发生;
  • NAFLD患者的肠道菌群组成改变,肠杆菌科等变形菌增多,菌群特征或能作为诊断标志物;
  • 肠道菌群失调伴随肠道通透性升高、细菌移位和内毒素血症,菌群产生的LPS激活TLR4/NLRP3炎性小体途径,从而增加肝脏脂肪和炎症;
  • 益生菌、Akk菌等下一代益生菌、益生元、合生制剂、粪菌移植、多酚、特定饮食和运动等干预方法,或能通过多种机制调节肠道菌群来改善NAFLD。
主编推荐语
mildbreeze
非酒精性脂肪性肝病(NAFLD)越来越普遍,Gastroenterology近期发表的综述,总结了目前对肠道菌群在NAFLD中的作用的研究进展,重点探讨了调节菌群以改善NAFLD的潜在干预疗法,值得专业人士关注。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gastroenterology [IF:17.373]

Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?

非酒精性脂肪性肝病:调节肠道菌群以改善疾病程度?

10.1053/j.gastro.2020.01.049

02-07, Review

Abstract & Authors:展开

Abstract:收起
Gut microbiota plays a role in the pathophysiology of metabolic diseases which also include nonalcoholic fatty liver diseases (NAFLD), through the gut-liver axis. To date, clinical guidelines recommend a weight loss goal of 7 to 10% to improve features of NAFLD. Nevertheless, since this target is not easily achieved by all patients, alternative therapeutic options are currently being evaluated. This review focusses on therapeutics that aims to modulate the gut microbiota and the gut-liver axis. We will herein discuss how probiotics, prebiotics, synbiotic, fecal microbiota transfer, polyphenols, specific diets and exercise interventions have been shown to modify gut microbiota signatures, improve NAFLD outcomes and detail, when available, the different mechanisms by which these beneficial outcomes might occur. Apart from probiotics which have already been tested in human RCTs, most of these potential therapeutics have been studied in animals. Their efficacy still warrants confirmation in humans using appropriate design.

First Authors:
Judith Aron-Wisnewsky

Correspondence Authors:
Judith Aron-Wisnewsky,Karine Clément

All Authors:
Judith Aron-Wisnewsky,Moritz Warmbrunn,Max Nieuwdorp,Karine Clément

评论